China Target Of Lilly Of U.S. For Biopharma-Industry Investments
This article was originally published in PharmAsia News
Executive Summary
China's biopharmaceutical industry is targeted by U.S.-based Eli Lilly & Co. for continued investments to build the firm's research-and-development and presence in the country